ABSTRACT
This study investigated the role of hyperhomocysteinaemia as a risk factor in Sudanese adults suffering from cardiovascular disease or malaria and children with protein-energy malnutrition. Mean total plasma homocysteine levels (micromol/L) were significantly higher in patients with coronary heart disease (17.64; SD 11.68) recurrent venous thrombosis (5.06; SD 10.55) and recurrent malaria (13.61; SD 4.82) than in healthy adult controls (7.85; SD 3.39). The mean homocysteine level was also significantly higher in children with protein-energy malnutrition (8.41; SD 1.61) than in healthy control children (5.72; SD 1.99).
Subject(s)
Coronary Disease/blood , Homocysteine/blood , Hyperhomocysteinemia/complications , Malaria/blood , Protein-Energy Malnutrition/blood , Venous Thrombosis/blood , Adult , Analysis of Variance , Case-Control Studies , Child , Coronary Disease/epidemiology , Coronary Disease/etiology , Female , Folic Acid/blood , Hospitals, Teaching , Humans , Hyperhomocysteinemia/blood , Hyperhomocysteinemia/epidemiology , Malaria/epidemiology , Male , Middle Aged , Protein-Energy Malnutrition/epidemiology , Recurrence , Risk Factors , Sudan/epidemiology , Venous Thrombosis/epidemiology , Venous Thrombosis/etiology , Vitamin B 12/bloodABSTRACT
This study investigated the role of hyperhomocysteinaemia as a risk factor in Sudanese adults suffering from cardiovascular disease or malaria and children with protein-energy malnutrition. Mean total plasma homocysteine levels [micro mol/L] were significantly higher in patients with coronary heart disease [17.64; SD 11.68] recurrent venous thrombosis [5.06; SD 10.55] and recurrent malaria [13.61; SD 4.82] than in healthy adult controls [7.85; SD 3.39]. The mean homocysteine level was also significantly higher in children with protein-energy malnutrition [8.41; SD 1.61] than in healthy control children [5.72; SD 1.99]
Subject(s)
Cardiovascular Diseases , Malaria , Protein-Energy Malnutrition , Risk Factors , Enzyme-Linked Immunosorbent Assay , HomocysteineABSTRACT
The promastigote surface antigen-2 (PSA-2) is a Leishmania parasite antigen, which can induce Th1-mediated protection against murine leishmaniasis when used as a vaccine. To evaluate PSA-2 as a human vaccine candidate the specific T-cell response to PSA-2 was characterised in individuals immune to cutaneous leishmaniasis. Peripheral blood mononuclear cells from Sudanese individuals with a past history of self-healing cutaneous leishmaniasis proliferated vigorously in response to PSA-2 isolated from Leishmania major, whereas the antigen did not activate cells from presumably unexposed Danes. Peripheral blood mononuclear cells from individuals with previous L. major infection had varying proliferative responses to PSA-2 derived from L. donovani promastigotes. Peripheral blood mononuclear cells activated by PSA-2 from L. major produced high amounts of interferon-gamma and tumour necrosis factor-beta, and little interleukin-4, thereby showing a Th1 cytokine pattern. Parallel cultures showed clear Th1 and Th2 response patterns to purified protein derivative of tuberculin or tetanus toxoid, respectively. Flow cytometric analysis revealed that PSA-2 induced blastogenesis in the CD3 positive population and that these cells were the major source of interferon-gamma. The results show that Th1-like cells recognising PSA-2 are expanded during infection by L. major and that they maintain their Th1-like cytokine profile upon reactivation in vitro. Since immunity to cutaneous leishmaniasis is mediated by antigen-specific Th1-like cells, PSA-2 might be considered a vaccine candidate for human leishmaniasis.
Subject(s)
Antigens, Protozoan/immunology , Antigens, Surface/immunology , Leishmania major/immunology , Leishmaniasis, Cutaneous/immunology , Protozoan Proteins , Th1 Cells/immunology , Animals , CD3 Complex/analysis , Flow Cytometry , Humans , Immunity, Active , Interferon-gamma/biosynthesis , Interleukin-4/biosynthesis , Leukocytes, Mononuclear/immunology , Lymphocyte Activation , Lymphotoxin-alpha/biosynthesis , Protozoan Vaccines/immunology , SudanABSTRACT
Seven children, six boys and a girl, aged from 2 to 15 years with proven myelofibrosis are reported. The clinical presentation in each of them was more or less similar with weight loss, moderate or low-grade fever, and abdominal distension with pain or discomfort for some months. They had hepatosplenomegaly. The spleens, enlarged to more than 6 cm below the costal margin, were smooth, firm and not tender. There was a variable degree of generalized lymphadenopathy. They were diagnosed as myelofibrosis associated with tuberculosis. The clinical response to anti-tuberculous chemotherapy was remarkable. Extensive search should be made for evidence of tuberculosis in children presenting with myelofibrosis.